Arabic Arabic English English French French German German

ASC Therapeutics Receives IND Clearance From the U.S. Food and Drug Administration for ASC618 Second-Generation Gene Therapy for Hemophilia A

ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ASC618, an investigational second-generation gene therapy for patients with severe and moderately severe hemophilia A. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

AiCuris Starts Its First Pivotal Clinical Phase 3 Trial with Pritelivir for the Treatment of HSV Infections in Immunocompromised Subjects Based on Efficacy and Safety Data from a Phase 2 Trial

Next Post

Xeltis Initiates First-ever Pivotal Trial of a Synthetic Restorative Pulmonary Heart Valve

Related Posts